AI Model Reduces False Positives in Screening Mammograms
By Lori Solomon HealthDay Reporter
THURSDAY, April 25, 2024 -- A semiautonomous breast cancer screening system reduces false positives with screening mammograms, according to a study published online April 10 in Radiology: Artificial Intelligence.
Stefano Pedemonte, Ph.D., from Whiterabbit.ai in Santa Clara, California, and colleagues evaluated the ability of a semiautonomous artificial intelligence (AI) model to identify screening mammograms not suspicious for breast cancer. The analysis compared performance of humans and AI using three nonoverlapping datasets of 14,831 screening mammography examinations (1,026 cancers).
The researchers found minimal changes to the cancer detection rate with use of the AI device (noninferiority margin of 0.25 cancers per 1,000 examinations). For U.S. dataset 1 (11,592 mammograms; 101 cancers), the AI model reduced screening examinations requiring radiologist interpretation by 41.6 percent, diagnostic examination callbacks by 31.1 percent, and benign needle biopsies by 7.4 percent. For U.S. dataset 2 (1,362 mammograms; 330 cancers), reductions were 19.5, 11.9, and 6.5 percent, respectively. For the U.K. dataset (1,877 mammograms; 595 cancers), reductions were 36.8, 17.1, and 5.9 percent, respectively.
"This work demonstrates the potential of a semiautonomous breast cancer screening system to reduce false positives, unnecessary procedures, patient anxiety, and medical expenses," the authors write.
Several authors disclosed financial ties to Whiterabbit.ai.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.